Marianne De Backer, Vir Biotechnology CEO (Brian Benton Photography)
January 8, 2025 07:45 AM ESTUpdated 05:16 PM
R&D

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

Elizabeth Cairns

Senior biopharma journalist

In­ter­im da­ta on two T cell en­gagers that Vir Biotech­nol­o­gy li­censed from Sanofi last year have be­gun to jus­ti­fy the biotech’s strate­gic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Judge halts some NIH cuts af­ter 22 states sue

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

Decade af­ter $8B deal, Roche of­floads In­ter­Mune to mys­te­ri­ous spe­cial­ty phar­ma

Eli Lil­ly inks $630M deal for Phase 1 MASH can­di­date

Boehringer In­gel­heim touts suc­cess in sec­ond Phase 3 lung fi­bro­sis tri­al

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times